The additional value of TGFβ1 and IL-7 to predict the course of prostate cancer progression

Cancer Immunology, Immunotherapy

Volumn 61, Issue 6, 2012, Pages 905-910

  Schroten, Caroline ^a   Dits, Natasja F ^a   Steyerberg, Ewout W ^a   Kranse, Ries ^b   Van Leenders, Arno G J L H ^a   Bangma, Chris H ^a   Kraaij, Robert ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Integraal Kankercentrum Rotterdam   (Netherlands)

Author keywords

Gleason score; Interleukin 7; Prostate cancer; Survival; TGF 1

Indexed keywords

INTERLEUKIN 7; INTERLEUKIN 7 RECEPTOR; PROSTATE SPECIFIC ANTIGEN; TRANSFORMING GROWTH FACTOR BETA1; TUMOR MARKER;

ADULT; AGE; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER RISK; CANCER SPECIFIC SURVIVAL; CANCER TISSUE; CARCINOGENESIS; CLINICAL ARTICLE; CONTROLLED STUDY; GLEASON SCORE; HUMAN; HUMAN TISSUE; MALE; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RETROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

DISEASE PROGRESSION; HUMANS; INTERLEUKIN-7; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSTATECTOMY; PROSTATIC NEOPLASMS; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, INTERLEUKIN-7; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84862332628     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-011-1159-3     Document Type: Article

References (39)

1. Eckersberger E, Finkelstein J, Sadri H, Margreiter M, Taneja SS, Lepor H, Djavan B (2009) Screening for prostate cancer: A review of the ERSPC and PLCO trials. Rev Urol 11:127-133
2. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis LJ, Recker F, Berenguer A, Maattanen L, Bangma CH, Aus G, Villers A, Rebillard X, van der Kwast T, Blijenberg BG, Moss SM, de Koning HJ, Auvinen A (2009) Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 360:1320-1328
3. Gleason DF (1966) Classification of prostatic carcinomas. Cancer Chemother Rep 50:125-128
4. Pinthus JH, Witkos M, Fleshner NE, Sweet J, Evans A, Jewett MA, Krahn M, Alibhai S, Trachtenberg J (2006) Prostate cancers scored as Gleason 6 on prostate biopsy are frequently Gleason 7 tumors at radical prostatectomy: implication on outcome. J Urol 176:979-984; discussion 984
5. Rajinikanth A, Manoharan M, Soloway CT, Civantos FJ, Soloway MS (2008) Trends in Gleason score: concordance between biopsy and prostatectomy over 15 years. Urology 72:177-182
6. Allam CK, Bostwick DG, Hayes JA, Upton MP, Wade GG, Domanowski GF, Klein MA, Boling EA, Stilmant MM (1996) Interobserver variability in the diagnosis of high-grade prostatic intraepithelial neoplasia and adenocarcinoma. Mod Pathol 9:742-751 (Pubitemid 26246582)
7. Descazeaud A, Rubin MA, Allory Y, Burchardt M, Salomon L, Chopin D, Abbou C, de la Taille A (2005) What information are urologists extracting from prostate needle biopsy reports and what do they need for clinical management of prostate cancer? Eur Urol 48:911-915 (Pubitemid 41641634)
8. Tsivian M, Sun L, Mouraviev V, Madden JF, Mayes JM, Moul JW, Polascik TJ (2009) Changes in Gleason score grading and their effect in predicting outcome after radical prostatectomy. Urology 74:1090-1093
9. Orozco R, O'Dowd G, Kunnel B, Miller MC, Veltri RW (1998) Observations on pathology trends in 62, 537 prostate biopsies obtained from urology private practices in the United States. Urology 51:186-195 (Pubitemid 28093166)
10. Muntener M, Epstein JI, Hernandez DJ, Gonzalgo ML, Mangold L, Humphreys E, Walsh PC, Partin AW, Nielsen ME (2008) Prognostic significance of Gleason score discrepancies between needle biopsy and radical prostatectomy. Eur Urol 53:767-775; discussion 775-766
11. Boorjian SA, Karnes RJ, Crispen PL, Rangel LJ, Bergstralh EJ, Sebo TJ, Blute ML (2009) The impact of discordance between biopsy and pathological Gleason scores on survival after radical prostatectomy. J Urol 181:95-104; discussion 104
12. Twillie DA, Eisenberger MA, Carducci MA, Hseih WS, Kim WY, Simons JW (1995) Interleukin-6: a candidate mediator of human prostate cancer morbidity. Urology 45:542-549
13. Wise GJ, Marella VK, Talluri G, Shirazian D (2000) Cytokine variations in patients with hormone treated prostate cancer. J Urol 164:722-725 (Pubitemid 30637610)
14. Adler HL, McCurdy MA, Kattan MW, Timme TL, Scardino PT, Thompson TC (1999) Elevated levels of circulating interleukin-6 and transforming growth factor-beta1 in patients with metastatic prostatic carcinoma. J Urol 161:182-187 (Pubitemid 29422316)
15. Thompson TC, Truong LD, Timme TL, Kadmon D, McCune BK, Flanders KC, Scardino PT, Park SH (1992) Transforming growth factor beta 1 as a biomarker for prostate cancer. J Cell Biochem Suppl 16H:54-61 (Pubitemid 23047970)
16. Truong LD, Kadmon D, McCune BK, Flanders KC, Scardino PT, Thompson TC (1993) Association of transforming growth factor-beta 1 with prostate cancer: an immunohistochemical study. Hum Pathol 24:4-9 (Pubitemid 23046665)
17. Eastham JA, Truong LD, Rogers E, Kattan M, Flanders KC, Scardino PT, Thompson TC (1995) Transforming growth factor-beta 1: comparative immunohistochemical localization in human primary and metastatic prostate cancer. Lab Invest 73:628-635 (Pubitemid 3018923)
18. Perry KT, Anthony CT, Steiner MS (1997) Immunohistochemical localization of TGF beta 1, TGF beta 2, and TGF beta 3 in normal and malignant human prostate. Prostate 33:133-140 (Pubitemid 27415537)
19. Tang J, Nuccie BL, Ritterman I, Liesveld JL, Abboud CN, Ryan DH (1997) TGF-beta down-regulates stromal IL-7 secretion and inhibits proliferation of human B cell precursors. J Immunol 159:117-125 (Pubitemid 127493692)
20. Dubinett SM, Huang M, Dhanani S, Economou JS, Wang J, Lee P, Sharma S, Dougherty GJ, McBride WH (1995) Down-regulation of murine fibrosarcoma transforming growth factor-beta 1 expression by interleukin 7. J Natl Cancer Inst 87:593-597
21. Blobe GC, Schiemann WP, Lodish HF (2000) Role of transforming growth factor beta in human disease. N Engl J Med 342:1350-1358 (Pubitemid 30408720)
22. Jicha DL, Mule JJ, Rosenberg SA (1991) Interleukin 7 generates antitumor cytotoxic T lymphocytes against murine sarcomas with efficacy in cellular adoptive immunotherapy. J Exp Med 174:1511-1515
23. Naume B, Espevik T (1991) Effects of IL-7 and IL-2 on highly enriched CD56+ natural killer cells. A comparative study. J Immunol 147:2208-2214
24. Andersson A, Yang SC, Huang M, Zhu L, Kar UK, Batra RK, Elashoff D, Strieter RM, Dubinett SM, Sharma S (2009) IL-7 promotes CXCR3 ligand-dependent T cell antitumor reactivity in lung cancer. J Immunol 182:6951-6958
25. Schroten-Loef C, de Ridder CM, Reneman S, Crezee M, Dalgleish A, Todryk SM, Bangma CH, Kraaij R (2009) A prostate cancer vaccine comprising whole cells secreting IL-7, effective against subcutaneous challenge, requires local GM-CSF for intra-prostatic efficacy. Cancer Immunol Immunother 58:373-381
26. Di Carlo E, D'Antuono T, Pompa P, Giuliani R, Rosini S, Stuppia L, Musiani P, Sorrentino C (2009) The lack of epithelial interleukin-7 and BAFF/BLyS gene expression in prostate cancer as a possible mechanism of tumor escape from immunosurveillance. Clin Cancer Res 15:2979-2987
27. Hendriksen PJ, Dits NF, Kokame K, Veldhoven A, van Weerden WM, Bangma CH, Trapman J, Jenster G (2006) Evolution of the androgen receptor pathway during progression of prostate cancer. Cancer Res 66:5012-5020 (Pubitemid 43844921)
28. van der Heul-Nieuwenhuijsen L, Dits NF, Jenster G (2009) Gene expression of forkhead transcription factors in the normal and diseased human prostate. BJU Int 103:1574-1580
29. Rao AR, Motiwala HG, Karim OM (2008) The discovery of prostate-specific antigen. BJU Int 101:5-10 (Pubitemid 350233553)
30. Shariat SF, Walz J, Roehrborn CG, Zlotta AR, Perrotte P, Suardi N, Saad F, Karakiewicz PI (2008) External validation of a biomarker-based preoperative nomogram predicts biochemical recurrence after radical prostatectomy. J Clin Oncol 26:1526-1531
31. Svatek RS, Jeldres C, Karakiewicz PI, Suardi N, Walz J, Roehrborn CG, Montorsi F, Slawin KM, Shariat SF (2009) Pretreatment biomarker levels improve the accuracy of post-prostatectomy nomogram for prediction of biochemical recurrence. Prostate 69:886-894
32. Perry KT, Anthony CT, Case T, Steiner MS (1997) Transforming growth factor beta as a clinical biomarker for prostate cancer. Urology 49:151-155 (Pubitemid 27043118)
33. Mitropoulos D, Kiroudi A, Christelli E, Serafetinidis E, Zervas A, Anastasiou I, Dimopoulos C (2004) Expression of transforming growth factor beta in renal cell carcinoma and matched noninvolved renal tissue. Urol Res 32:317-322 (Pubitemid 39517954)
34. Lin Y, Nakachi K, Ito Y, Kikuchi S, Tamakoshi A, Yagyu K, Watanabe Y, Inaba Y, Kazuo T (2009) Variations in serum transforming growth factor-beta1 levels with gender, age and lifestyle factors of healthy Japanese adults. Dis Markers 27:23-28
35. Porreca E, Di Febbo C, Vitacolonna E, Baccante G, Di Castelnuovo A, Angelini A, Febo F, Di Nisio M, Cuccurullo F (2002) Transforming growth factor-beta1 levels in hypertensive patients: association with body mass index and leptin. Am J Hypertens 15:759-765 (Pubitemid 34970103)
36. Vudattu NK, Magalhaes I, Schmidt M, Seyfert-Margolis V, Maeurer MJ (2007) Reduced numbers of IL-7 receptor (CD127) expressing immune cells and IL-7-signaling defects in peripheral blood from patients with breast cancer. Int J Cancer 121:1512-1519 (Pubitemid 47328710)
37. Hull GW, McCurdy MA, Nasu Y, Bangma CH, Yang G, Shimura S, Lee HM, Wang J, Albani J, Ebara S, Sato T, Timme TL, Thompson TC (2000) Prostate cancer gene therapy: comparison of adenovirus-mediated expression of interleukin 12 with interleukin 12 plus B7-1 for in situ gene therapy and gene-modified, cell-based vaccines. Clin Cancer Res 6:4101-4109
38. Selleck WA, Canfield SE, Hassen WA, Meseck M, Kuzmin AI, Eisensmith RC, Chen SH, Hall SJ (2003) IFN-gamma sensitization of prostate cancer cells to Fas-mediated death: a gene therapy approach. Mol Ther 7:185-192 (Pubitemid 36395353)
39. Steyerberg EW (2009) Clinical prediction models: a practical approach to development, validation, and updating. Springer, New York